Trexquant Investment LP Has $1.38 Million Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Trexquant Investment LP grew its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 267.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 179,966 shares of the company’s stock after purchasing an additional 130,960 shares during the quarter. Trexquant Investment LP owned approximately 0.49% of iTeos Therapeutics worth $1,382,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in ITOS. JPMorgan Chase & Co. boosted its stake in shares of iTeos Therapeutics by 342.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,068,796 shares of the company’s stock valued at $15,888,000 after purchasing an additional 1,601,477 shares in the last quarter. State Street Corp lifted its stake in shares of iTeos Therapeutics by 21.9% in the third quarter. State Street Corp now owns 1,175,353 shares of the company’s stock worth $12,000,000 after acquiring an additional 211,452 shares during the period. Raymond James Financial Inc. acquired a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $1,159,000. Peapod Lane Capital LLC acquired a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $836,000. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of iTeos Therapeutics in the fourth quarter worth approximately $299,000. 97.16% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on ITOS shares. HC Wainwright reaffirmed a “buy” rating and issued a $46.00 price objective on shares of iTeos Therapeutics in a research note on Thursday, March 6th. JPMorgan Chase & Co. lowered their target price on iTeos Therapeutics from $22.00 to $15.00 and set an “overweight” rating for the company in a report on Thursday, March 6th. Wedbush reiterated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a report on Wednesday, March 5th. Finally, Wells Fargo & Company lowered their target price on iTeos Therapeutics from $19.00 to $17.00 and set an “overweight” rating for the company in a report on Thursday, March 6th.

iTeos Therapeutics Price Performance

Shares of NASDAQ:ITOS opened at $5.39 on Thursday. The company has a market capitalization of $205.87 million, a PE ratio of -1.71 and a beta of 1.43. The business has a fifty day moving average price of $6.82 and a two-hundred day moving average price of $7.90. iTeos Therapeutics, Inc. has a 1 year low of $4.80 and a 1 year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last announced its quarterly earnings data on Wednesday, March 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.14) by $0.13. Sell-side analysts anticipate that iTeos Therapeutics, Inc. will post -3.49 earnings per share for the current year.

iTeos Therapeutics Company Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.